A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma

MLA

T. Cloughesy, et al. “A Phase I Safety and Pharmacokinetic Study of XL765 (SAR245409), a Novel PI3K/TORC1/TORC2 Inhibitor, in Combination with Temozolomide (TMZ) in Patients (Pts) with Newly Diagnosed Malignant Glioma.” Journal of Clinical Oncology, vol. 28, May 2010, p. 3085. EBSCOhost, https://doi.org/10.1200/jco.2010.28.15_suppl.3085.

APA

T. Cloughesy, Antonio Omuro, Patrick Y. Wen, Phioanh L. Nghiemphu, Linh Nguyen, Andrew D. Norden, Ingo K. Mellinghoff, & K. Rajangam. (2010). A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. Journal of Clinical Oncology, 28, 3085. https://doi.org/10.1200/jco.2010.28.15_suppl.3085

Chicago

T. Cloughesy, Antonio Omuro, Patrick Y. Wen, Phioanh L. Nghiemphu, Linh Nguyen, Andrew D. Norden, Ingo K. Mellinghoff, and K. Rajangam. 2010. “A Phase I Safety and Pharmacokinetic Study of XL765 (SAR245409), a Novel PI3K/TORC1/TORC2 Inhibitor, in Combination with Temozolomide (TMZ) in Patients (Pts) with Newly Diagnosed Malignant Glioma.” Journal of Clinical Oncology 28 (May): 3085. doi:10.1200/jco.2010.28.15_suppl.3085.